Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 28Carcinoma, Renal Cell 19Carcinoma, Non-Small-Cell Lung 13Carcinoma, Hepatocellular 10Brain Neoplasms 7Skin Neoplasms 6Neoplasm Metastasis 6Clear-cell metastatic renal cell carcinoma 6Neoplasms 5Kidney Neoplasms 5Colorectal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Lung Neoplasms 4Carcinoma, Transitional Cell 4Triple Negative Breast Neoplasms 3Multiple Myeloma 3Mesothelioma 3Liver Neoplasms 3Breast Neoplasms 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Sarcoma 2Recurrence 2Prostatic Neoplasms 2Mesothelioma, Malignant 2Lymphoma, Non-Hodgkin 2Glioblastoma 2Colonic Neoplasms 2

Interventions

Injections 6Fluorodeoxyglucose F18 4Cyclophosphamide 4Bevacizumab 4toripalimab 3fludarabine 2Specimen Handling 2Nivolumab 2zimberelimab 1tumor-cells apoptosis factor, human 1trametinib 1tislelizumab 1temsirolimus 1spartalizumab 1pembrolizumab 1pazopanib 1palbociclib 1olaparib 1lenvatinib 1etoposide phosphate 1enzalutamide 1envafolimab 1donafenib 1disitamab vedotin 1dabrafenib 1cemiplimab 1avelumab 1atezolizumab 1anlotinib 1WW Domain-Containing Oxidoreductase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Solid Tumor × Ipilimumab × Clear all
NCT05584670 2026-01-20

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Sanofi

Phase 1/2 Recruiting
542 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡